4 completed, 1 recruiting. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Recruiting 1 |
Follow John Levine: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MAGIC Ruxolitinib for aGVHD Ruxolitinib, Methylprednisolone - Acute Graft-versus-host Disease, Allogeneic Bone Marrow Transplantation | Phase 2 | Recruiting | John Levine | 98 | 2025-05-14 | 2026-03-23 |
| Pediatric GVHD Low Risk Steroid Taper Trial Prednisone - Acute Graft vs Host Disease, Allogeneic Bone Marrow Transplantation | Phase 2 | Completed | John Levine | 50 | 2022-10-20 | 2026-06-03 |
| Itacitinib for Low Risk GVHD Itacitinib - Low Risk Acute Graft-versus-host Disease, Graft-versus-host-disease | Phase 2 | Completed | John Levine | 70 | 2019-03-25 | 2023-02-06 |
| A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD Alpha 1-Antitrypsin - Graft-versus-host-disease, GVHD | Phase 2 | Completed | John Levine | 30 | 2018-08-17 | 2021-07-12 |
| Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease natalizumab, steroids - Acute Graft Versus Host Disease | Phase 2 | Completed | John Levine | 76 | 2016-08-01 | 2022-10-21 |
Prednisone (2) · Methylprednisolone (1) · Methylprednisolone Acetate (1) · Methylprednisolone Hemisuccinate (1) · Natalizumab (1) · Steroids (1) · alpha 1-Antitrypsin (1) · itacitinib (1) · ruxolitinib (1)
United States (5) · Canada (1)
John E Levine, MD (1) · John E Levine, MD, MS (1) · Muna Qayed, MD, MS (1)
PMID 33351103, PMID 36095841, PMID 37235690
P01CA039542 (2)